about
Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALSUbiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosisMutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx studyThe diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseResearch criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteriaDiagnosis and management of dementia with Lewy bodies: third report of the DLB ConsortiumCommon variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions.Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.Genetic and clinical features of progranulin-associated frontotemporal lobar degenerationNeuropsychological characterization of cognitively-impaired-not-demented (CIND) individuals: clinical comparison data.Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.Familial frontotemporal dementia with neuronal intranuclear inclusions is not a polyglutamine expansion disease.Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup.An exploration of cognitive subgroups in Alzheimer's diseaseMutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration.Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder.Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin.Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014Epidemiology and genetics of frontotemporal dementia/Pick's disease.Treatment of Alzheimer's disease: current status and new perspectives.Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer's disease.Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans.Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance.Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease.Periventricular hyperintensities are associated with elevated cerebral amyloid.Clinical phenotypes of Cerebral Amyloid Angiopathy.Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementiaClinical presentation of prodromal frontotemporal dementia.Therapeutic potential of statins in Alzheimer's disease.Dependence as a unifying construct in defining Alzheimer's disease severityEfficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.Nonpharmacological therapies in Alzheimer's disease: a systematic review of efficacy.Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development.A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease.Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease.Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial.Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.Defeating Alzheimer's disease and other dementias: a priority for European science and society.
P50
Q24633692-8B420EAE-8C5C-4D3A-9A08-6612CEFD8076Q28131672-391F8AF6-B4ED-4BAE-B2D0-F6773B384537Q28253651-0CFAAC0F-E5C7-455F-9EF9-A890D51AFD09Q28302829-1EE48B33-7B5C-4D1C-906E-0D719B6483FCQ29614406-60A1AE10-1801-46F3-BC92-19CC4690E718Q29614408-F43C5017-ED40-47DF-B10D-C002EFDB33A7Q29614409-AD3A750A-8D25-4613-820C-A6C5228B1EBDQ30434949-F0290946-1000-488E-9620-58D453566679Q30458193-DFA45D00-8595-4C5C-BB91-B07D41AE87CBQ30503638-403DFCDE-EC4C-4946-8DD6-C768D1016D5BQ30978069-90DEC075-F45D-4C44-8CAA-F0BA54C3D910Q31063014-057B8615-8F8B-4C2A-9C15-5FB4EE24FAC0Q33255969-2760FFCD-35C7-4F82-BB2A-8742D48159BBQ33869820-E78DD29E-0742-4474-A638-94723820FD06Q33969633-03E617B8-11B9-4DF5-84ED-101305CF1887Q33993389-E021BBF5-F320-439A-B2A2-C36888BCA45FQ33999208-86859AF3-8A8E-41D4-B22A-5328DE6671AAQ34114364-A1A4BC9E-2DFF-4162-B82C-39445857048BQ34346014-43EBC678-0B53-4CEB-B194-62D8152C13C7Q34408888-1795A7E9-BE90-473F-9CD8-EB95339A81FEQ35165806-5C19B353-3BB6-4DFA-90EB-F488B558A4BDQ35206995-B83ACA70-E3CE-42C9-B04C-A7F48B0DE471Q35460043-D5F913B0-B13B-443E-9F35-79951BE319A5Q35844926-9EF09661-00C0-4381-AFCC-398FEA2417F2Q35894767-AE41C105-8F08-4705-9334-BEBFC94E9E0EQ36226630-085D6077-8171-4440-8A0A-47ADF0F48F5CQ36580364-B6A5B8A9-3792-44CF-AB3C-A28538CA6AF3Q36753077-A1ED01E1-F486-4094-8120-01F3F0AFE25FQ36967985-D554982F-72BA-4F9A-B7BA-D080A740CA32Q37048083-83E81721-2D72-4468-8C45-F413FC7CAD78Q37423422-7A3889D7-DD26-4C1E-AD40-592877539DD6Q37448832-955EDDBB-F3B6-4EE8-A6DD-95724B7FB12EQ37511619-AE5292EB-B826-49FC-BD9A-93FB07C3B7DEQ37788481-B2C6CB95-94C1-4AFC-9DB5-7C48E3792A25Q38050217-11A391FC-D266-4F9C-8FA7-458EDE17A011Q38076634-C7F64340-F05E-4F30-8195-0FC2A61BEFB3Q38081667-95E086FA-6A01-4777-BFF9-5A9DBEFA04DBQ38402983-56079B2E-73FB-4EC1-BB27-8396BBCC9023Q38465993-C011E6FF-422C-4FA4-92C1-0CF7DB14EE81Q38778638-E8FF7CD1-E7C5-4609-902F-09941B18194F
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Howard Feldman
@ast
Howard Feldman
@en
Howard Feldman
@es
Howard Feldman
@nl
Howard Feldman
@sl
type
label
Howard Feldman
@ast
Howard Feldman
@en
Howard Feldman
@es
Howard Feldman
@nl
Howard Feldman
@sl
prefLabel
Howard Feldman
@ast
Howard Feldman
@en
Howard Feldman
@es
Howard Feldman
@nl
Howard Feldman
@sl
P106
P1153
7201854388
P21
P214
880148705737537080000
P31
P496
0000-0002-9258-4538